Clinical trial
A Phase II Study of Ribavirin in Refractory of Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes
NCT00559091 is registered in ClinicalTrials.gov with Jewish General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Ribavirin in Refractory of Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes
- Lead sponsor
- Jewish General Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2007
- Completion date
- February 28, 2010
- Enrollment
- 18 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
acute myelocytic leukemia